CompletedPhase 2

Ziprasidone in the Psychosis Prodrome

United States51 participantsStarted 2008-03

Plain-language summary

This study aims to determine whether ziprasidone is superior to placebo over 24 weeks for patients with the psychosis prodrome.

Who can participate

Age range16 Years – 40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Structured Interview for Psychosis-risk Syndromes criteria for Clinical High Risk for Psychosis * clinically referred Exclusion Criteria: * prolonged corrected QT interval * history of syncope

What they're measuring

Conversion to Psychosis

Timeframe: 6 months

Trial details

NCT IDNCT00635700

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-11

Results submitted2016-09-06

View on ClinicalTrials.gov More Psychosis Prodrome trials